Asgard Therapeutics in a €30 million Series A co-led by RV Invest and Johnson & Johnson's JJDC, w/ Novo Holdings, Boehringer Ingelheim and Industrifonden
05 March 2024
Belgium
Netherlands
Austria
Switzerland
Estonia
Finland
Iceland
Latvia
Lithuania
Norway
France
Ireland
Italy
Portugal
Spain
United Kingdom